Menu
Not yet recruiting NCT07344987

Effect of Indoor Air Quality Improvement on Health in Patients With Interstitial Lung Disease

No phase Interventional ILD

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Air Purifier (with Filter) Arm, Purifier (without Filter) Arm.
Who it may be relevant to
Registry conditions: ILD. Basic parameters: from 19 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Randomized Crossover Trial of Indoor Air Quality Improvement on Health in Patients With Interstitial Lung Disease

Overview

Air pollution threatens the respiratory health of patients with interstitial lung disease (ILD). High-efficiency air purifiers, featuring easy operation and excellent particulate matter removal efficiency, have been shown in previous studies to potentially delay lung function deterioration and reduce acute exacerbation risk in respiratory disease patients. This randomized crossover study employs air purifiers to filter indoor gaseous pollutants, allergens, and other contaminants, aiming to alleviate respiratory irritation, improve daily life comfort, and enhance overall health status in ILD patients.

Interventions

  • Behavioral Air Purifier (with Filter) Arm
    Place an air purifier with high-efficiency filters in the home, and turn it on for at least 18 hours every day.
  • Behavioral Purifier (without Filter) Arm
    Place an air purifier without a filter in the home.

Primary outcome measures

  • Symptom Improvement-related Indicators (e.g., Improvement in Respiratory Symptom Score) [Time frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)]
  • Pulmonary Function Indicators (e.g., Pulmonary Diffusing Capacity) [Time frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)]
  • Quality of Life Indicators (e.g., CAT Score) [Time frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)]
  • Blood Sample Indicators (e.g., Concentration of Interleukin-8) [Time frame: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)]

Eligibility criteria

Inclusion criteria

  • Patients diagnosed with interstitial lung disease (ILD).
  • Stable disease status, defined as no hospitalization due to acute exacerbation within the past month.

Exclusion criteria

  • Patients with complications of severe organ failure (including heart, liver, or kidney failure), malignant tumors, or mental disorders.
  • A history of respiratory tract infection within the past two weeks.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Crossover
Masking
Single blind
Primary purpose
Prevention

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07344987 · CAMS-PUMC-IRM-IAQ-ILD-2025

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗